An observational study in Recurrent Ventricular Tachycardia, sponsored by John Sapp. Completed at 1 site in Canada. Per ClinicalTrials.gov, last updated 2022-03-15.
Sponsored by John Sapp · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 15th largest by enrollment of the 15 observational ones that give a count, is one of 3 that started in 2016, is one of 15 observational ones, and was the 18th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:
Adagio Medical · Sites in Canada, United States
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–99
Thermedical, Inc. · Sites in Canada, United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
University Hospital, Basel, Switzerland · Sites in Canada, United States, Austria and 13 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 167 across 147 observational studies indexed under Tachycardia, Ventricular.
Median enrollment 130 across the 39 interventional studies, 1,735 across the 15 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
John Sapp is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
John Sapp has 6 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
10 of the studies in Tachycardia, Ventricular with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05047198Phase 3Ottawa Heart Institute Research CorporationCatheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial | 2026-12-31 |
| NCT06281977Phase 3Ottawa Heart Institute Research CorporationStudy Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm | 2027-05-08 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05258422McGill University Health Centre/Research Institute of the McGill University Health CentreStereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) | 2026-12-31 |
| NCT03713866John SappPeri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm non-randomized prospective observational cohort study to assess the outcomes of patients undergoing intramural needle catheter ablation of recurrent ventricular tachycardia that has failed antiarrhythmic drug therapy and standard radiofrequency (RF) catheter ablation. Following ablation, patients will be monitored for 6 months. The duration of the study is up to 4 years.
This is an observational prospective cohort study of patients undergoing needle catheter ablation. Patients with recurrent sustained or incessant ventricular tachycardia who have recurrent monomorphic ventricular tachycardia that has failed antiarrhythmic drug therapy and prior catheter ablation who are undergoing intramural needle ablation for VT will be offered participation. Data will be collected during the procedure and during follow-up. Patients will be monitored in hospital for complications and during 6 months follow-up.
Data Collection:
Baseline Data: Baseline demographic information and a narrative medical history will be collected on all patients, including documentation of prior cardiac history, and arrhythmia history, as well as prior medications and cardiac procedures.
Procedural data: Details of the procedure including both procedural methods and arrhythmias induced, ablation parameters, needle deployments, recordings and response to procedure.
Followup data: Adverse events will be collected for events which are documented during enrollment and follow-up. During follow-up, hospitalizations will be collected, need for further procedures, implantable defibrillator therapies and procedures will be collected, as well as follow-up echocardiography findings.
Patients with recurrent ventricular tachycardia who have failed radiofrequency catheter ablation who are undergoing intramural needle catheter ablation procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
Freedom from hospitalization for recurrent VT during 6 months following ablation
Control of VT as defined by: freedom from hospitalization for recurrent VT during the 6 months following ablation
Time frame: 6 months
Absence of serious adverse events attributable to the procedure which occur within 30 days of the ablation procedure
Absence of all serious adverse events that are potentially procedure related and occur within 30 days of the ablation procedure.
Time frame: 6 months
Acute Procedural Success
Termination of at least one clinical or presumptive clinical monomorphic VT by RF ablation or rendering that VT no longer inducible
Time frame: 6 hours
Acute procedural complications
Any complications occurring within 24 hours post procedure described as probably or possibly related to the VT catheter ablation procedure
Time frame: 24 hours
Number of inducible VT morphologies
Number of VT morphologies induced during catheter ablation
Time frame: 6 hours
ICD therapy - shocks
Number of VT events treated with appropriate ICD shocks at 3 months post procedure
Time frame: 3 months
ICD therapy - shocks
Number of VT events treated with appropriate ICD shocks at 6 months post procedure
Time frame: 6 months
ICD therapy - ATP
Number of VT events treated with antitachycardia pacing (without shock) during 3 months follow-up post-ablation procedure
Time frame: 3 months
ICD therapy - ATP
Number of VT events treated with antitachycardia pacing (without shock) during 6 months follow-up post-ablation procedure
Time frame: 6 months
ICD Therapy
Number of VT events treated with antitachycardia pacing (with shock) during 3 months follow-up post-ablation procedure
Time frame: 3 months
ICD Therapy
Number of VT events treated with antitachycardia pacing (with shock) during 6 months follow-up post-ablation procedure
Time frame: 6 months
VT storm
Number of VT storm events during 3 months follow-up
Time frame: 3 months
VT storm
Number of VT storm events during 6 months follow-up
Time frame: 6 months
VT events
Difference in number of VT events during 3 months prior to and following procedure
Time frame: 3 months
VT events
Difference in number of VT events during 6 months prior to and following procedure
Time frame: 6 months
Recurrent VT
Time to first recurrent VT
Time frame: 6 months
Appropriate ATP
Time to first appropriate ATP
Time frame: 6 months
Appropriate ICD shock
Time to first appropriate ICD shock
Time frame: 6 months
VT Storm
Time to first VT storm
Time frame: 6 months
Antiarrhythmic Drug Therapy
Changes in antiarrhythmic drug therapy post-procedure
Time frame: 6 months
Total appropriate ICD shocks
Total number of appropriate ICD shocks during 3 months follow up
Time frame: 3 months
Total appropriate ICD shocks
Total number of appropriate ICD shocks during 6 months follow up
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2016 to primary completion in Apr 2018, 21 months.
Of 69 observational studies under Tachycardia, Ventricular, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 108. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
John Sapp